The company is on track to initiate the Advanced-3 registrational trial in patients who have not previously received BCG in the second half of 2026.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data?